Mediwound (MDWD)
NASDAQ:MDWD
Want to see MDWD full AI Analyst Report?
Top Page
Mediwound
(NASDAQ:MDWD)
Select Model
Select Model
Rating:47Neutral
Price Target:
$15.00
▼(-8.54% Downside)
Action:Reiterated
Date:03/07/26
The score is held down primarily by weak financial performance (shrinking/volatile revenue, large losses, and sustained negative free cash flow) and a technically weak price trend (below key moving averages with negative MACD). The earnings call provides a partial offset via reaffirmed multiyear guidance, manufacturing expansion and trial progress, but execution, funding, and regulatory timing risks remain meaningful; valuation is also constrained by ongoing losses and no dividend yield data.
Positive Factors
Manufacturing scale-up
A sixfold increase in NexoBrid production capacity materially strengthens the company's ability to supply commercial demand, support national stockpiling and secure larger institutional contracts. Once regulatory release occurs, higher throughput can lower unit costs, improve gross margins and enable sustainable volume-driven revenue growth over multiple years.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow demonstrates the business requires external funding to sustain operations. Ongoing cash burn forces repeated financing or dilution, constrains strategic optionality and elevates solvency risk if anticipated contract or grant receipts are delayed, impairing long-term execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Manufacturing scale-up
A sixfold increase in NexoBrid production capacity materially strengthens the company's ability to supply commercial demand, support national stockpiling and secure larger institutional contracts. Once regulatory release occurs, higher throughput can lower unit costs, improve gross margins and enable sustainable volume-driven revenue growth over multiple years.
Read all positive factors
Mediwound (MDWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$216.32M
Dividend YieldN/A
Average Volume (3M)83.89K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth-16.14%
EPS Growth31.77%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.10
Shares Outstanding12,845,664
10 Day Avg. Volume97,082
30 Day Avg. Volume83,890
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)4.81
Price to Sales (P/S)12.38
P/FCF Ratio-10.48
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue10.85
Enterprise Value/Gross Profit56.57
Enterprise Value/Ebitda-8.57
Forecast
1Y Price Target
$30.00Price Target Upside82.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$24.76M
Mediwound Business Overview & Revenue Model
Company Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or d...
How the Company Makes Money
MediWound makes money primarily by commercializing its approved product NexoBrid and by partnering with third parties for distribution and market access. Revenue is generated from product sales (either direct sales where MediWound commercializes i...
Mediwound Earnings Call Summary
Earnings Call Date:Mar 05, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 27, 2026
Earnings Call Sentiment Neutral
The call reflects meaningful operational and strategic progress — a sixfold manufacturing capacity expansion, active Phase III enrollment for EscharEx, expanded indication work (DFU and pressure ulcers), numerous industry collaborations, substantive real-world data for NexoBrid, and a strengthened cash position following a $30M financing — all of which support a multiyear growth thesis. Offsetting these positives are near-term financial challenges: steep Q4 revenue decline (≈-67%), a full-year revenue drop (≈-16%), higher R&D spend and widening operating and EBITDA losses, reliance on government awards and pending regulatory approvals for the new facility, and elevated cash burn. Overall, operational momentum is evident but financial performance and timing risks temper the outlook.Positive Updates
Phase III VALUE Trial Progress
Enrollment ongoing in global Phase III VALUE study targeting 216 patients across ~40 U.S. and European sites; prespecified interim assessment and enrollment completion expected by year-end 2026, preserving ~90% statistical power.
Negative Updates
Sharp Q4 Revenue Decline
Q4 2025 revenue of $1.9M versus $5.8M in Q4 2024 (≈-67%), primarily driven by lower development services revenue attributable to the U.S. government shutdown which delayed budget approvals and new contracts.
Read all updates
Q4-2025 Updates
Positive
Negative
Phase III VALUE Trial Progress
Enrollment ongoing in global Phase III VALUE study targeting 216 patients across ~40 U.S. and European sites; prespecified interim assessment and enrollment completion expected by year-end 2026, preserving ~90% statistical power.
Read all positive updates
Company Guidance
MediWound reaffirmed multiyear revenue guidance of $24–$26M for 2026, $32–$35M for 2027 and $50–$55M for 2028 (the 2028 range includes potential initial EscharEx contribution), noting the guidance assumes continued BARDA and U.S. Department of War support and expects BARDA‑related revenue to begin in Q2 2026 with stronger second‑half revenue as the expanded manufacturing site (sixfold capacity increase) comes online pending regulatory clearances expected in 2026. On the clinical side, the VALUE Phase III targets 216 patients across ~40 U.S./EU sites with a prespecified interim sample‑size assessment after ~65% of patients complete treatment to preserve ~90% statistical power (if needed, a +20–40 patient increase would add a few months and a few million dollars; a +100 patient increase could add ≥6 months and roughly $10M). Balance‑sheet and runway metrics cited include $53.6M cash/cash equivalents/deposits at 12/31/2025, $21.4M cash used in 2025 operations, and financing proceeds of $30.0M (registered direct offering) plus $3.5M from Series A warrant exercises.Mediwound Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.96M | 20.22M | 18.69M | 26.50M | 23.76M |
| Gross Profit | 3.25M | 2.63M | 3.58M | 13.16M | 8.77M |
| EBITDA | -21.47M | -27.93M | -4.80M | -18.25M | -11.38M |
| Net Income | -23.88M | -30.22M | -6.72M | -19.60M | -13.55M |
Balance Sheet | |||||
| Total Assets | 86.25M | 73.50M | 66.46M | 50.02M | 19.74M |
| Cash, Cash Equivalents and Short-Term Investments | 53.14M | 43.16M | 41.54M | 33.90M | 11.05M |
| Total Debt | 8.77M | 6.93M | 6.35M | 846.00K | 1.39M |
| Total Liabilities | 34.33M | 42.34M | 34.86M | 39.10M | 24.33M |
| Stockholders Equity | 43.63M | 31.15M | 31.59M | 10.91M | -4.58M |
Cash Flow | |||||
| Free Cash Flow | -20.04M | -19.90M | -16.93M | -12.44M | -9.40M |
| Operating Cash Flow | -14.53M | -13.62M | -10.46M | -11.88M | -8.92M |
| Investing Cash Flow | -19.54M | -8.40M | -34.32M | -481.00K | 3.55M |
| Financing Cash Flow | 29.62M | 19.39M | 22.92M | 35.76M | -1.05M |
Mediwound Technical Analysis
Negative
16.40
Price Trends
16.80
Negative
17.23
Negative
17.62
Negative
Market Momentum
-0.08
Negative
47.46
Neutral
67.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Negative. The current price of 16.4 is below the 20-day moving average (MA) of 16.69, below the 50-day MA of 16.80, and below the 200-day MA of 17.62, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 47.46 is Neutral, neither overbought nor oversold. The STOCH value of 67.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDWD.
Mediwound Risk Analysis
Mediwound disclosed 58 risk factors in its most recent earnings report. Mediwound reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mediwound Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $687.65M | -9.27 | -33.07% | ― | ― | -20.34% | |
55 Neutral | $300.26M | -2.22 | -96.80% | ― | ― | -1.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $48.43M | -0.72 | 315.97% | ― | ― | 38.95% | |
47 Neutral | $216.32M | -8.24 | -65.79% | ― | -16.14% | 31.77% | |
47 Neutral | $329.07M | -20.11 | -152.10% | ― | 54.64% | -250.94% |
* Healthcare Sector Average
MDWD
Mediwound
16.58
-3.79
-18.61%
LCTX
Lineage Therap
1.30
0.60
86.25%
ELDN
Eledon Pharmaceuticals
3.89
0.84
27.54%
DSGN
Design Therapeutics
10.97
7.09
182.73%
TVGN
Tevogen Bio Holdings
9.61
-55.89
-85.33%
Mediwound Corporate Events
MediWound Sets May 6, 2026 Shareholder Meeting to Vote on Board, Auditor and CEO Bonus
Mar 30, 2026
On March 30, 2026, MediWound filed a Form 6-K announcing it had published proxy materials and notice for its 2026 annual general meeting of shareholders, to be held on May 6, 2026 in New York. The meeting will cover the re-election of five directo...
MediWound Posts 2025 Loss but Strengthens Cash and Advances EscharEx, NexoBrid Capacity
Mar 5, 2026
On March 5, 2026, MediWound reported fourth‑quarter and full‑year 2025 results, highlighting $17 million in 2025 revenue, a net loss of $23.9 million, and a year‑end cash balance of $53.6 million strengthened by a $30 million dir...
MediWound Shareholders Approve Expansion of 2024 Equity Incentive Pool
Feb 19, 2026
On February 19, 2026, MediWound Ltd. held an extraordinary general meeting in Israel at which shareholders representing about 30% of the company’s 12.8 million outstanding ordinary shares as of the January 16, 2026 record date were present, ...
MediWound Calls February 19, 2026 Extraordinary Meeting to Expand 2024 Share Incentive Plan
Jan 15, 2026
On January 15, 2026, MediWound Ltd. filed materials for an extraordinary general meeting of shareholders scheduled for February 19, 2026 in New York, at which investors will be asked to approve an increase of 300,000 ordinary shares reserved for i...
MediWound Lays Out Growth Path With EscharEx Progress, NexoBrid Scale-Up and Strong Cash Position
Jan 12, 2026
On January 12, 2026, MediWound issued a corporate and financial update ahead of the J.P. Morgan Healthcare Conference, detailing clinical, operational and financial milestones achieved through 2025 and its outlook for the coming years. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.